Urology Times staff

"I do think there's a big opportunity, if [telemedicine is] used correctly, to overcome some of these workforce shortages," says Chad Ellimoottil, MD, MS.

Casey Seideman, MD, discusses the gender pay gap in urology and the path forward to address the issue.

Health care providers focus on genomic testing in heavily treated, metastatic castrate-resistant prostate cancer from the multidisciplinary approach to cancer care.

Health care providers focus on genomic testing in newly diagnosed, high grade, high-risk prostate cancer from the multidisciplinary approach to cancer care.

“I think one of the most surprising things to us as we started to look at the data is that we had a very low rate of no shows amongst telemedicine visits,” says Randie White, MD.

A recently published study showed an increased risk of cardiac failure in men with BPH and exposure to 5-alpha reductase inhibitors and/or α-blockers.

“We found that medications allegedly causing priapism and the litigation surrounding that is significant because it means that the patient-physician relationship was not well established,” says Ariana Matz, MD.

Robert J. Motzer, MD, discusses health-related quality of life analyses from the phase 3 CLEAR trial of frontline pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma.

The UroLift System is a noninvasive treatment for patients with BPH that relieves prostate obstruction by lifting and holding the prostate tissue that is blocking the urethra.

In this interview, Amy M. Pearlman, MD, also discusses how she uses social media at professional conferences.

“While patient facing apps hold great potential to support self-management behaviors, particularly in stone disease, thoughtful consideration across an array of domains should really be taken prior to supporting or even recommending one of these apps to a patient,” says Jared S. Winoker, MD.

In an interview conducted during the 2021 ASCO Annual Meeting, Robert A. Figlin, MD, deputy director, Cedars-Sinai Cancer, shared his expertise on trends in the treatment of patients with genitourinary cancers.

“It's quick to act and it's quick to leave the system,” says Ranjith Ramasamy, MD, of the nasal testosterone gel Natesto.

In the phase 3 VISION trial, adding the targeted radioligand therapy 177Lu-PSMA-617 to standard of care led to a nearly 40% reduction in the risk of death.

Nearly half of the surveyed men reported that urinary symptoms led them to avoid events or activities they enjoy.

“The complete clinical response rate of 48% was somewhat surprising, although consistent with our assumptions in terms of the statistical design of the study,” says Matthew Galsky, MD.

Urologist Amy M. Pearlman, MD, discusses how she uses social platforms such as Twitter, Facebook, and Tiktok to entertain and inform.

Dr. Michael Devitt, discusses whether circulating tumors cells are ready for primetime as a diagnostic/prognostic biomarker in urothelial carcinoma.

The study follows a successful phase 1b/2 study, data from which were presented at the 2021 ASCO Annual Meeting.

“It's important for any urologist to gain a broader exposure and awareness to the tools and techniques available to help improve efficiency in the operating room and reduce the amount of wasteful time in between cases,” says Niki N. Parikh, MD, MBA, MSBA.

Sivakumar was a researcher on a study presented at the 2021 ASCO Annual Meeting that assessed ancestry, patterns of gene alterations, comprehensive genomic profiling, and treatment patterns in nearly 12,000 patients with prostate cancer.

Robert A. Figlin, MD, discusses results from the phase 2 CANTATA study of cabozantinib plus telaglenastat in patients with advanced/metastatic renal cell carcinoma.

Laura Bukavina, MD, MPH, and Justin Dubin, MD, also discuss their own usage of social media and share advice for medical professionals using social media.

Lantheus, the developer of piflufolastat F 18, selected oncology provider GenesisCare to administer the first commercially available dose of the agent.

“I think the data from this particular abstract pretty much reinforce that if you get avelumab as maintenance therapy, the time that patients spend in first- and second-line therapy is prolonged compared to patients who get best supportive care,” says Petros Grivas, MD, PhD.

Chung-Han Lee, MD, PhD, discusses the ongoing open-label phase 2 KEYNOTE-B61 study of frontline pembrolizumab plus lenvatinib in non-clear cell renal cell carcinoma.

“A lot of medicine that you do in person is very provider-centric in the sense that you tend to just walk from room to room and see patients, whereas with virtual care, you need to change the workflow a little bit,” says Chad Ellimoottil, MD, MS.

Petros Grivas, MD, PhD, discusses posthoc findings from the phase 3 JAVELIN Bladder 100 trial presented during the 2021 ASCO Annual Meeting.

Virtual men’s health options have “improved access for patients who otherwise cannot reach doctors or who are otherwise embarrassed to go see someone in person,” says Ranjith Ramasamy, MD.

Toni K. Choueiri, MD, discusses the clinical and regulatory implications of the phase 3 KEYNOTE-564 trial, which explored pembrolizumab following nephrectomy in patients with clear cell renal cell carcinoma.